Detox can stabilize acute intoxication and withdrawal, but it may not resolve the question of what is driving a patient’s psychiatric symptoms. A provisional diagnosis, ongoing support, and planned reassessment help clinicians respond to symptoms without mistaking early recovery for a settled clinical picture.
Detox is a transition point, not a diagnostic finish line.
Depression, anxiety, sleep disruption, agitation, cognitive changes, and psychotic symptoms can occur during intoxication, withdrawal, and early recovery. They can also reflect an independent psychiatric condition, a medical problem, medication effects, or more than one factor at once. The overlap makes it difficult to distinguish a substance-induced psychiatric disorder from a co-occurring condition based on one evaluation.
For clinicians treating co-occurring disorders, the practical task is not to force an early either-or answer. It is to assess acuity, establish a useful working formulation, treat current needs, and watch how symptoms change as the patient stabilizes. The same diagnostic question arises with substance-induced mood disorder and substance-induced anxiety disorder, where symptoms can resemble independent depression or anxiety.
Assess safety & acuity first.
Before focusing on etiology, assess immediate safety and determine whether the patient needs urgent psychiatric or medical evaluation. Suicidal thoughts or behavior, severe agitation, mania, hallucinations or delusions, confusion, impaired judgment, inability to care for basic needs, or signs of complicated withdrawal can require prompt escalation. A diagnostic question should never delay stabilization or a needed safety intervention.
The ASAM hospital and emergency department implementation guide recommends screening for and stabilizing co-occurring psychiatric conditions, including suicide risk, while addressing the substance use disorder. This parallel approach matters when symptoms themselves interfere with engagement, safety, or participation in treatment.
Build a timeline before settling on a diagnosis.
A careful timeline often provides more diagnostic value than the first symptom checklist. Document the substances used, pattern and amount of use, route, last use, withdrawal course, periods of abstinence, prescribed and nonprescribed medications, and the timing of each symptom. Ask whether symptoms began before heavy substance use, emerged during intoxication or withdrawal, improved during prior periods of abstinence, or recurred when the patient was not using.
When available and appropriate, review prior treatment records and seek collateral history with the patient’s consent. Family psychiatric history, previous diagnoses, medication response, trauma history, baseline functioning, and recent changes in sleep and cognition can add context. No single detail proves that symptoms are substance-induced or independent, but the pattern across time can strengthen or weaken each possibility.
Use abstinence as information, not as a reason to withhold care.
Symptoms related to intoxication or withdrawal often improve as the acute effects resolve, but the course varies by substance, duration and severity of use, co-occurring conditions, and individual factors. SAMHSA’s TIP 42 guidance on substance-induced and independent mental disorders describes these diagnoses as provisional in many cases and recommends observing symptom changes and reevaluating over time. It also cautions clinicians not to withhold treatment while the origin of symptoms remains unclear.
The diagnostic framework discussed in TIP 42 identifies persistence for a substantial period after acute withdrawal or severe intoxication, such as a month, as one piece of evidence that may favor an independent disorder. That example is not a universal waiting rule. It should not be used to postpone treatment, defer a safety assessment, or require every patient to complete a fixed period of abstinence before receiving psychiatric care.
A substance-induced diagnosis also does not rule out a separate co-occurring condition. Patients can have both, and the working formulation may change as more history becomes available. Document what is known, what remains uncertain, and when the next reassessment will occur.
Know when symptoms warrant continued psychiatric evaluation.
Ongoing evaluation is especially important when symptoms predate heavy use, persist or intensify as withdrawal resolves, recur during abstinence, or cause substantial impairment. A history of similar episodes, a strong family history, limited improvement with stabilization, or symptoms that are more severe or prolonged than expected for the reported substance exposure can also support referral or psychiatric consultation. These features guide further assessment; they do not establish a diagnosis on their own.
Persistent psychosis deserves particular attention. In a systematic review and meta-analysis of transition from substance-induced psychosis to schizophrenia, transition rates varied by substance, with higher estimates reported for cannabis-, hallucinogen-, and amphetamine-associated psychoses. Those findings do not predict an individual patient’s outcome, but they support longitudinal follow-up rather than assuming that psychosis will resolve once intoxication ends.
Treat current symptoms while the formulation develops.
A patient does not need a final psychiatric label before receiving support. Continue evidence-based substance use treatment and address clinically significant psychiatric symptoms in parallel, using appropriate psychotherapy, medication evaluation, safety planning, and referral or consultation. ASAM’s guidance on co-occurring conditions emphasizes concurrent care rather than managing psychiatric conditions only after substance use treatment is complete.
At follow-up, reassess symptom severity, functioning, sleep, cognition, substance use, medication effects, and safety. Update the formulation when the evidence changes, and coordinate handoffs so the next clinician understands both the immediate plan and the unresolved diagnostic questions. Reassessment is part of treating co-occurring disorders, not a sign that the initial assessment failed.
A clearer picture can emerge with time and coordinated care.
When psychiatric symptoms persist after detox, clinicians do not have to choose between dismissing them as withdrawal and declaring a primary disorder too early. A longitudinal approach can make room for both careful diagnosis and timely care: stabilize risk, understand the patient’s history, treat what is affecting them now, and reassess as recovery progresses.
How Enterhealth supports patients with co-occurring needs.
At Enterhealth, addiction and mental health concerns are considered together throughout treatment. Care begins with medical and psychological assessment, then adapts to the patient’s needs as the clinical picture develops. At Enterhealth Ranch, medically supervised detox and residential care include 24/7 clinical support, ongoing assessment, and coordination across the care team. Outpatient services can provide continued psychiatric evaluation, medication management, and support as treatment progresses.
For clinicians seeking addiction treatment for a patient with complex mental health needs, contact Enterhealth’s team to discuss treatment and referral options.

